Morgan Steven, Lopert Ruth, Greyson Devon
Open Med. 2008;2(1):e4-7. Epub 2008 Jan 30.
ONGOING DEBATES IN THE PHARMACEUTICAL SECTOR ABOUT INTELLECTUAL PROPERTY, PRICING AND REIMBURSEMENT, AND PUBLIC RESEARCH INVESTMENTS HAVE A COMMON DENOMINATOR: the pursuit of innovation. However, there is little clarity about what constitutes a true pharmaceutical innovation, and as a result there is confusion about what kind of new products should be pursued, protected and encouraged through health policy and clinical practice. If the concept of pharmaceutical innovation can be clarified, then it may become easier for health policy-makers and practitioners to evaluate, adopt and procure products in ways that appropriately recognize, encourage and give priority to truly valuable pharmaceutical innovations.
制药行业中关于知识产权、定价与报销以及公共研究投资的持续争论有一个共同特点：对创新的追求。然而，对于什么构成真正的药物创新却鲜有明确界定，因此对于应该通过卫生政策和临床实践来追求、保护和鼓励何种新产品存在困惑。如果能够厘清药物创新的概念，那么卫生政策制定者和从业者或许就能更轻松地以适当认可、鼓励并优先考虑真正有价值的药物创新的方式来评估、采用和采购产品。
